中文摘要：

目的 探讨苯磺贝他斯汀治疗过敏性鼻炎（AR）的临床有效性和安全性.方法 选择2009年1月～2012年1月陕西省延安市志丹县人民医院收治的AR患者200例,饭后服用苯磺贝他斯汀10 mg/次,2次/d,连续服用2周；分别在治疗前后对患者临床症状、体征和病情严重程度进行评分,检查血清中免疫球蛋白E（IgE）和鼻灌洗液嗜酸性粒细胞阳离子蛋白（ECP）含量,同时观察患者临床疗效和不良反应.结果 与治疗前比较,治疗后患者临床症状总分、鼻塞、流涕、鼻痒、喷嚏、体征和视觉模拟量表（VAS）评分显著降低（P＜0.01）,血清IgE和鼻灌洗液ECP含量显著下降（P＜0.01）;治疗后患者临床有效率为91.50％,药物相关不良反应发生率为16.50％.结论 苯磺贝他斯汀治疗AR具有较好的临床效果和安全性,可显著改善患者临床症状和体征.

英文摘要：

Objective To explore the clinical efficacy and safety of Bepotastine Besilate Tablets treating for allergic rhinitis （AR）. Methods 200 cases of patients with AR were chosen from January 2009 to January 2012 in Zhidan County People＇s Hospital of Yah＇an City of Shaanxi Province, and they were given 10 milligrams of Bepotastine Besilate Tablets per time, two times a day, for two weeks; the score of clinical symptoms, signs and disease severity were evalu- ated and the levels of serum immunoglobulin E （IgE） and nasal lavage eosinophil cationic protein （ECP） were exam- ined before and after treatment, while the clinical efficacy and adverse reactions were observed. Results Compared with pre-treatment, the scores of clinical symptom score, nasal congestion, runny nose, nasal itching, sneezing, signs and visual scale proposed scale （VAS） significantly decreased （P 〈 0.01）, and the levels of serum IgE and nasal lavage ECP significantly decreased after treatment （P 〈 0.01）; the clinical effective rate was 91.50%, drug-related adverse reactions was 16.50% after treatment. Conclusion Bepotastine Besilate Tablets treating for AR has better clinical effi- cacy and safety, and it can significantly improve the clinical symptoms and signs.